Studies were conducted to characterize the effects of γ-tocotrienol treatment alone and in combination with specific PPARγ agonists and antagonists on the growth and survival of MCF-7 and MDA-MB-231 human breast cancer cells. This evidence concerns the gene PPARG and breast cancer.